Asuragen partners with wave life sciences to develop companion diagnostics for huntington’s disease

Asuragen, inc. and wave life sciences have entered into an agreement for the development and commercialization of companion diagnostics for wave’s investigational allele-selective therapeutic programs targeting huntington’s disease (hd). hd is a devastating disorder caused by an expansion of cag repeats in the htt gene that results in the progressive breakdown of nerve cells in the brain. it deteriorates a person's physical and mental abilities, usually during their prime working years, is ultimately fatal and has no cure. the companion diagnostics that asuragen will develop build on the experience gained by wave using a single-nucleotide polymorphism (snp) phasing methodology in wave’s current clinical trials in hd and a previous observational study. this collaboration aims to use asuragen’s market-leading repetitive sequence diagnostic expertise to provide scalable snp phasing to support potential global phase 3 development programs and future commercialization at a global level.
WVE Ratings Summary
WVE Quant Ranking